A Study of AZD0486 in Subjects With B-Cell Non-Hodgkin Lymphoma
← catalyst calendarNCT04594642 · readout in 670 d
Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →.
Phase
Phase 1
Status
Active, not recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
226actual
Sites
25
Countries
Australia, Japan, South Korea +2
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2021-03-02 | actual | When the study began enrolling |
| Primary completion | 2028-06-19 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2028-06-19 | estimated | The whole study's end, after follow-up |
| First posted | 2020-10-20 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-17 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- B-cell Non Hodgkin Lymphoma
- Diffuse Large B Cell Lymphoma
- High-grade B-cell Lymphoma
- Follicular Lymphoma
Intervention
- Drug: AZD0486 IV — also filed as TNB-486
Primary outcomes
what the primary-completion date above is the date OFIncidence of subjects with Dose-limiting toxicities (DLT)
measured 28 days
Incidence of subjects with adverse events (AEs) and/or serious adverse events (SAEs)
measured From screening until 90 Days after end of treatment
Maximum Observed Serum Concentration of AZD0486 (Cmax)
measured 4 Weeks
Area under the concentration versus time curve from time zero to the last quantifiable time point prior to the next dose (AUClast)
measured 4 Weeks
Apparent terminal half-life (t1/2) of AZD0486
measured From screening until 90 Days after end of treatment
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed